Professor Yuwen Zhou: CAPCET Study Demonstrates a More Effective and Cost-Efficient First-Line Strategy for Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer

Professor Yuwen Zhou will present the CAPCET study, which focuses on first-line treatment for patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer. By comparing modified CAPOX plus cetuximab with the conventional mFOLFOX6-based regimen, the study demonstrated significant therapeutic advantages. The results showed superior progression-free survival (PFS), overall survival (OS), and objective response rate (ORR), while also offering reduced toxicity and better cost-effectiveness. These findings support the regimen as an efficient, safe, and economically favorable first-line treatment option for clinical practice.

Professor Haihong Wang: UNION TNT Study Highlights the Potential of Precision Combination Therapy for HER2-Expressing Locally Advanced Rectal Cancer

Professor Haihong Wang will present the UNION TNT study, which explores short-course radiotherapy combined with disitamab vedotin and immunochemotherapy for patients with HER2-expressing locally advanced rectal cancer. Preliminary findings demonstrate remarkable clinical benefit, with a pathological complete response (pCR) rate of 75% among patients who underwent surgery, while several additional patients achieved clinical complete response (cCR). These encouraging results underscore the significant potential of precision targeted combination therapy in the immunotherapy era to improve treatment efficacy while maximizing opportunities for organ preservation.

Professor Yi Yi Yu: Building a High-Quality IIT Research System at Zhongshan Hospital

This presentation provided an in-depth overview of Zhongshan Hospital's investigator-initiated trial (IIT) research system, highlighting its practical experience in infrastructure development, digital platforms, and talent cultivation. Through the implementation of the CREMS management platform, a dual electronic data capture (EDC) system, and the institutional innovation known as the "Zhongshan Ten Measures," the hospital has established a closed-loop quality management system covering the entire clinical research process. This model emphasizes standardized management spanning scientific review through to research translation, providing a robust foundation for medical innovation.
Pujiang Prostate Cancer Summit | Professor Jianming Guo: Breaking Through CRPC Resistance and Why Cytoreductive Surgery for Oligometastatic Disease Is Emerging as the Next Frontier

Pujiang Prostate Cancer Summit | Professor Jianming Guo: Breaking Through CRPC Resistance and Why Cytoreductive Surgery for Oligometastatic Disease Is Emerging as the Next Frontier

The 2026 Pujiang Prostate Cancer Summit was successfully held in Shanghai on June 26–27. Hosted by the Shanghai Anti-Cancer Association and organized by Fudan University Shanghai Cancer Center, the meeting brought together leading experts through keynote lectures, multidisciplinary (MDT) discussions, and live surgical demonstrations to highlight the latest advances in prostate cancer management. Among the meeting's major themes, personalized and precision treatment strategies attracted particular attention.
Pujiang Prostate Cancer Summit | Professor Dingwei Ye: Expanding Early Screening, Standardizing Care, and Advancing Clinical Research—Three Pillars to Narrow China’s Prostate Cancer Survival Gap

Pujiang Prostate Cancer Summit | Professor Dingwei Ye: Expanding Early Screening, Standardizing Care, and Advancing Clinical Research—Three Pillars to Narrow China’s Prostate Cancer Survival Gap

The 2026 Pujiang Prostate Cancer Summit was held in Shanghai on June 26–27 under the theme "Standardization, Precision, Chinese Innovation, and Global Collaboration." The meeting brought together leading experts in genitourinary oncology to showcase the latest advances in standardized prostate cancer management and innovative treatment strategies.
Clear Horizons, Comprehensive Urologic Care | Professor Xin Yao: ADT Remains the Cornerstone of Prostate Cancer Management, While LHRH Antagonists Deliver Both Clinical Efficacy and Quality of Life

Clear Horizons, Comprehensive Urologic Care | Professor Xin Yao: ADT Remains the Cornerstone of Prostate Cancer Management, While LHRH Antagonists Deliver Both Clinical Efficacy and Quality of Life

In this edition of Clear Horizons, Comprehensive Urologic Care, Professor Xin Yao from Tianjin Medical University Cancer Institute and Hospital discusses the mechanistic and clinical differences between LHRH agonists and antagonists, as well as practical strategies for managing ADT-related adverse events to maximize both treatment efficacy and patient quality of life.
APPLE 2026 | Prof. Stephen L. Chan: The Art and Science of Conversion Therapy in Cholangiocarcinoma 

APPLE 2026 | Prof. Stephen L. Chan: The Art and Science of Conversion Therapy in Cholangiocarcinoma 

Cholangiocarcinoma is characterized by its high malignancy, with the majority of patients presenting with unresectable disease at initial diagnosis. In recent years, conversion therapy—which utilizes systemic treatment to downsize tumors—has emerged as a pivotal, offering select patients a pathway to curative-intent resection. However, striking the right balance between therapeutic efficacy and overtreatment remains a significant clinical challenge. At APPLE 2026, Prof. Stephen L. Chan, from the Chinese University of Hong Kong (CUHK) Faculty of Medicine, offered an in-depth analysis of these issues during an exclusive interview with our journal. Prof. Chen advocates for earlier genomic testing for alterations such as FGFR2 and IDH1, and proposes a multidimensional assessment framework combining radiology with circulating biomarkers like ctDNA and MRD to precisely identify the optimal surgical window. Furthermore, he recommends a stratified postoperative strategy guided by pathological response (MPR/pCR) to maximize recurrence-free survival.
APACC 2026 | Prof. Jason Ong: Tackling PrEP Accessibility Challenges and Exploring AI-Driven New Pathways for STI Prevention and Control 

APACC 2026 | Prof. Jason Ong: Tackling PrEP Accessibility Challenges and Exploring AI-Driven New Pathways for STI Prevention and Control 

The 2026 Asia-Pacific AIDS and Co-infections Conference (APACC 2026) was successfully held in Tokyo, Japan. Focusing on cutting-edge practices and technological innovations in the prevention and control of HIV and sexually transmitted infections, the conference gathered global experts in the field to explore pathways for optimizing public health services. Our journal specially invited Professor Jason Ong from the Melbourne Sexual Health Centre in Australia for an in-depth interview.
APACC 2026| Researcher Johanna Beulah Sornillo: Rapid ART Initiation to Fortify HIV Prevention and Control in the Asia-Pacific 

APACC 2026| Researcher Johanna Beulah Sornillo: Rapid ART Initiation to Fortify HIV Prevention and Control in the Asia-Pacific 

The 11th Asia-Pacific AIDS & Co-Infections Conference (APACC 2026) was successfully convened in Tokyo, Japan. Bringing together HIV prevention and control experts from across the region, the conference focused on core regional challenges including standardized antiretroviral therapy (ART) and whole-course management for people living with HIV, serving as an exchange platform to advance the optimization of HIV diagnosis and treatment in the Asia-Pacific.
APPLE 2026 | Prof. Masatoshi Kudo: Reconstructing Systemic-Locoregional Therapeutic Strategies for Hepatocellular Carcinoma in the Immuno-Oncology Era 

APPLE 2026 | Prof. Masatoshi Kudo: Reconstructing Systemic-Locoregional Therapeutic Strategies for Hepatocellular Carcinoma in the Immuno-Oncology Era 

As hepatocellular carcinoma (HCC) treatment enters the wave of immuno-oncology (IO) combinations, the paradigm of combining systemic therapy with locoregional treatments (LRT) is undergoing a qualitative leap—evolving from incremental gains to a fundamental reconstruction. Held from July 3–5, 2026, the 16th Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting convened in Shanghai, bringing together leading experts from across the Asia-Pacific, Europe, and North America to discuss novel strategies for liver cancer prevention and management.